OverviewSuggest Edit

Lava Therapeutics is a biotech company that develops T-cell engagers for the therapy of solid tumors and hematologic malignancies. It provides immune-oncology biopharmaceuticals delivering the primary targeted treatment in combination with immune recruiting and activating functionality.

TypePublic
Founded2016
HQUtrecht, NL
Websitelavatherapeutics.com

Latest Updates

Employees (est.) (Dec 2020)28
Revenue (FY, 2020)€3.2 M
Share Price (Sept 2021)$6
Cybersecurity ratingAMore

Key People/Management at Lava Therapeutics

Steve Hurly

Steve Hurly

CEO
Ton Adang

Ton Adang

CDO
Hans van der Vliet

Hans van der Vliet

CSO
Edward F. Smith

Edward F. Smith

CFO
Benjamin Winograd

Benjamin Winograd

CMO
Paul Parren

Paul Parren

Head of R&D
Show more

Lava Therapeutics Office Locations

Lava Therapeutics has offices in Utrecht and Philadelphia
Utrecht, NL (HQ)
Yalelaan 60
Show all (2)

Lava Therapeutics Financials and Metrics

Lava Therapeutics Revenue

Lava Therapeutics's revenue was reported to be €3.19 m in FY, 2020
EUR

Revenue (FY, 2020)

3.2m

Net income (FY, 2020)

(13.6m)

EBIT (FY, 2020)

(12.8m)

Market capitalization (21-Sept-2021)

150.7m

Closing stock price (21-Sept-2021)

6.0

Cash (31-Dec-2020)

12.9m

EV

141.1m
Lava Therapeutics's current market capitalization is $150.7 m.
EURFY, 2019FY, 2020

Revenue

3.2m

General and administrative expense

1.1m2.3m

R&D expense

7.5m13.6m

Operating expense total

8.6m16.0m
EURFY, 2019FY, 2020

Cash

6.5m12.9m

Accounts Receivable

61.0k929.0k

Prepaid Expenses

55.0k95.0k

Current Assets

6.8m14.8m
EURFY, 2019FY, 2020

Net Income

(8.7m)(13.6m)

Depreciation and Amortization

233.0k402.0k

Accounts Payable

(169.0k)230.0k

Cash From Operating Activities

(7.7m)(8.5m)
EURFY, 2019

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.5 x
Show all financial metrics

Lava Therapeutics Operating Metrics

FY, 2020

Patent Applications (Foreign)

17

Patent Applications (US)

2

Patents (Foreign)

4

Patents (US)

2
Show all operating metrics

Lava Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Lava Therapeutics, Inc.

Lava Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Lava Therapeutics Online and Social Media Presence

Embed Graph

Lava Therapeutics Blogs

Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d

Roeland Lameris, Jurjen M Ruben, Iris de Weerdt, Rob Roovers, Arnon P Kater, Thilo Riedl, Victoria Iglesias, Benjamin Winograd, Ton EP Adang, Tanja D de ... The post Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager target…

LAVA Therapeutics B.V. Appoints Edward F. Smith as Chief Financial Officer

Veteran biopharma CFO brings over 20 years of experience leading finance functions at publicly traded pharmaceutical companies Utrecht, The Netherlands and Philadelphia, USA – March ... The post LAVA Therapeutics B.V. Appoints Edward F. Smith as Chief Financial Officer appeared first on Lava Therape…

LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting

Utrecht, The Netherlands and Philadelphia, USA – March 10, 2021 – LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta ... The post LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate …

LAVA Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program Entering the Clinic

Utrecht, The Netherlands and Philadelphia, USA – February 22, 2021 – LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in ... The post LAVA Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program E…

Great new publication in Clinical Cancer Research about the potential of targeting CD1d and Vγ9Vδ2-T cells to treat CLL authored by our CSO Hans van der Vliet, MD, PhD

https://clincancerres.aacrjournals.org/content/early/2021/02/02/1078-0432.CCR-20-4576 “A bispecific single domain antibody boosts autologous Vγ9Vδ2-T cell responses towards CD1d in chronic lymphocytic leukemia” The post Great new publication in Clinical Cancer Research about the potential of targeti…

Recognition of LAVA’s Leadership in Immuno-Oncology

Utrecht, The Netherlands and Philadelphia, USA – January 8, 2021 – More Recognition of LAVA’s Leadership in Immuno-Oncology: LAVA’s EVP and Head of R&D Paul Parren, PhD is Featured in Genetic Engineering and Biotechnology News (GEN)’s “Monoclonal Antibodies: Developers Explore New Territories”  …
Show more

Lava Therapeutics Frequently Asked Questions

  • When was Lava Therapeutics founded?

    Lava Therapeutics was founded in 2016.

  • Who are Lava Therapeutics key executives?

    Lava Therapeutics's key executives are Steve Hurly, Ton Adang and Hans van der Vliet.

  • How many employees does Lava Therapeutics have?

    Lava Therapeutics has 28 employees.

  • What is Lava Therapeutics revenue?

    Latest Lava Therapeutics annual revenue is €3.2 m.

  • What is Lava Therapeutics revenue per employee?

    Latest Lava Therapeutics revenue per employee is €113.8 k.

  • Who are Lava Therapeutics competitors?

    Competitors of Lava Therapeutics include Viosera Therapeutics, Shanghai Henlius Biotech and Cellectar Biosciences.

  • Where is Lava Therapeutics headquarters?

    Lava Therapeutics headquarters is located at Yalelaan 60, Utrecht.

  • Where are Lava Therapeutics offices?

    Lava Therapeutics has offices in Utrecht and Philadelphia.

  • How many offices does Lava Therapeutics have?

    Lava Therapeutics has 2 offices.